|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_ocn989872330 |
| 003 |
OCoLC |
| 005 |
20231120010201.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
170612s2017 enk ob 001 0 eng d |
| 010 |
|
|
|a 2017934820
|
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d YDX
|d IDEBK
|d EBLCP
|d OPELS
|d OCLCF
|d MERER
|d OCLCQ
|d UPM
|d OCLCQ
|d D6H
|d OCLCO
|d U3W
|d OCLCQ
|d OTZ
|d WYU
|d CNCGM
|d OCLCO
|d OCLCQ
|d OCLCO
|d ESU
|d LQU
|d OCLCQ
|d OCLCA
|d OCLCQ
|d OCLCA
|d OCLCQ
|d S2H
|d OCLCO
|d VT2
|d OCLCO
|d OCLCQ
|d SFB
|d OCLCQ
|d OCLCO
|
| 016 |
7 |
|
|a 101711768
|2 DNLM
|
| 019 |
|
|
|a 990029443
|a 990499844
|a 1066621975
|a 1105197232
|a 1105566912
|a 1235838083
|
| 020 |
|
|
|a 9780323527309
|q (electronic bk.)
|
| 020 |
|
|
|a 0323527302
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323527293
|
| 020 |
|
|
|z 0323527299
|
| 035 |
|
|
|a (OCoLC)989872330
|z (OCoLC)990029443
|z (OCoLC)990499844
|z (OCoLC)1066621975
|z (OCoLC)1105197232
|z (OCoLC)1105566912
|z (OCoLC)1235838083
|
| 050 |
|
4 |
|a RS201.L55
|
| 060 |
|
4 |
|a 2017 G-081
|
| 060 |
|
4 |
|a QU 93
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.7
|2 23
|
| 100 |
1 |
|
|a Shah, Muhammad Raza,
|e author.
|
| 245 |
1 |
0 |
|a Lipid-based nanocarriers for drug delivery and diagnosis /
|c Muhammad Raza Shah, Muhammad Imran and Shafi Ullah.
|
| 264 |
|
1 |
|a Oxford, United Kingdom :
|b Elsevier,
|c [2017]
|
| 264 |
|
4 |
|c �2017
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Micro & nano technologies series
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Vendor-supplied metadata.
|
| 505 |
0 |
|
|a Front Cover; Lipid-based Nanocarriers for Drug Delivery and Diagnosis; Copyright Page; Contents; Biographies; Preface; 1 Solid lipid nanoparticles; 1.1 Introduction; 1.2 Advantages; 1.3 Structural Composition of Solid Lipid Nanoparticles; 1.3.1 Lipids; 1.3.2 Surfactants; 1.3.3 Other Ingredients Used; 1.4 Incorporation of Drugs in Solid Lipid Nanoparticles; 1.4.1 Homogeneous Matrix Model; 1.4.2 Drug-Enriched Shell Model; 1.4.3 Drug-Enriched Core Model; 1.5 Preparation Techniques of Solid Lipid Nanoparticles; 1.5.1 High-Pressure Homogenization; 1.5.1.1 Hot homogenization.
|
| 505 |
8 |
|
|a 1.5.1.2 Cold homogenization1.5.2 Precipitation From Homogeneous Systems; 1.5.2.1 Precipitation from warm microemulsions; 1.5.2.2 Precipitation from water-miscible organic solvents; 1.5.3 Microwave-Assisted Microemulsion Technique; 1.5.4 Solvent Emulsification-Evaporation Method; 1.5.5 Double Emulsion-Based Method; 1.5.6 Emulsification-Diffusion Technique; 1.5.7 Solvent Displacement/Injection Method; 1.5.8 High Shear Homogenization/Ultrasound Method; 1.5.9 Membrane Contactor Method; 1.5.10 Solid Lipid Nanoparticle Preparation by Using Supercritical Fluid; 1.5.11 Coacervation Method.
|
| 505 |
8 |
|
|a 1.5.12 Phase Inversion Temperature Method1.6 Sterilization; 1.6.1 Moist Heat Sterilization; 1.6.2 Gamma-Radiation; 1.6.3 Filtration; 1.7 Lyophilization and Spray Drying of Solid Lipid Nanoparticles; 1.8 Characterization; 1.8.1 Particle Size and Size Distribution; 1.8.2 Particle Shape and Morphology; 1.8.3 Zeta Potential; 1.8.4 Polymorphism and Crystallinity of Lipids; 1.8.5 Functionality Assay; 1.9 Drug Release From Solid Lipid Nanoparticles; 1.10 Problems With Solid Lipid Nanoparticles Preparation and Performance; 1.10.1 High Pressure-Induced Drug Degradation; 1.10.2 Gelation Phenomena.
|
| 505 |
8 |
|
|a 1.10.3 Coexistence of Several Colloidal Species1.11 Solid Lipid Nanoparticles Application; 1.11.1 Improved Bioavailability; 1.11.2 Controlled Release; 1.11.3 Passive Targeting; 1.11.4 Active Targeting; References; Further Reading; 2 Nanostructured lipid carriers; 2.1 Introduction; 2.2 Distinct Advantages of Nanostructured Lipid Carriers; 2.2.1 Enhanced Drug Loading Capacity; 2.2.2 Modulation of Drug Release Profile; 2.2.3 Long-Term Stability Drug During Storage; 2.2.4 Decrease Surfactants Concentration Use; 2.3 Types of Nanostructured Lipid Carriers; 2.3.1 Imperfect Type.
|
| 505 |
8 |
|
|a 2.3.2 "Amorphous" Type2.3.3 "Multiple" Type; 2.4 Nanostructured Lipid Carriers Drug Incorporation Models; 2.5 Nanostructured Lipid Carriers Formulation; 2.5.1 Composition; 2.5.2 Preparation Methods; 2.5.2.1 High-pressure homogenization; 2.5.2.2 Ultrasonication; 2.5.2.3 Solvent diffusion method; 2.6 Structural Investigations of Nanostructured Lipid Carriers; 2.6.1 Nanostructured Lipid Carriers Morphology; 2.6.2 Particle Size; 2.6.3 Zeta Potential; 2.6.4 Differential Scanning Calorimetry; 2.6.5 X-Ray Diffraction; 2.6.6 Magnetic Resonance Investigation; 2.6.7 Raman and IR Spectroscopy.
|
| 650 |
|
0 |
|a Liposomes.
|
| 650 |
|
0 |
|a Nanostructures.
|
| 650 |
1 |
2 |
|a Liposomes
|x pharmacokinetics
|0 (DNLM)D008081Q000493
|
| 650 |
1 |
2 |
|a Nanostructures
|x therapeutic use
|0 (DNLM)D049329Q000627
|
| 650 |
2 |
2 |
|a Drug Delivery Systems
|0 (DNLM)D016503
|
| 650 |
|
2 |
|a Liposomes
|0 (DNLM)D008081
|
| 650 |
|
2 |
|a Nanostructures
|0 (DNLM)D049329
|
| 650 |
|
6 |
|a Liposomes.
|0 (CaQQLa)201-0009732
|
| 650 |
|
6 |
|a Nanostructures.
|0 (CaQQLa)201-0232666
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Liposomes
|2 fast
|0 (OCoLC)fst00999411
|
| 650 |
|
7 |
|a Nanostructures
|2 fast
|0 (OCoLC)fst01032635
|
| 700 |
1 |
|
|a Imran, Muhammad,
|e author.
|
| 700 |
1 |
|
|a Ullah, Shafi,
|e author.
|
| 776 |
0 |
8 |
|i Print version:
|a Shah, Muhammad Raza.
|t Lipid-based nanocarriers for drug delivery and diagnosis.
|d Oxford, United Kingdom : Elsevier, [2017]
|z 0323527299
|z 9780323527293
|w (OCoLC)978498760
|
| 830 |
|
0 |
|a Micro & nano technologies.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323527293
|z Texto completo
|
